Condensed Balance Sheets - USD ($) $ in Thousands	Mar. 31, 2024	Dec. 31, 2023
Current assets
Cash and cash equivalents	$ 46,930	$ 66,886
Marketable securities, short-term	205,582	176,636
Prepaid expenses and other current assets	3,319	3,093
Total current assets	255,831	246,615
Marketable securities, long-term	44,108	62,553
Right-of-use asset	353	381
Restricted cash	234	233
Property and equipment, net	117	122
Other assets	324	221
Total assets	300,967	310,125
Current liabilities
Accounts payable	3,079	1,379
Accrued clinical trial expenses	2,367	4,387
Accrued expenses and other current liabilities	2,905	6,339
Finance lease liability, short-term	0	756
Operating lease liability, short-term	121	110
Total current liabilities	8,472	12,971
Operating lease liability, long-term	252	284
Debt, long-term	30,209	29,897
Total liabilities	38,933	43,152
Commitments and contingencies (Note 10)
Stockholders’ equity
Preferred stock, $0.0001 par value; 10,000,000 shares authorized and no shares issued and outstanding as of March 31, 2024 and December 31, 2023	0	0
Common stock, $0.0001 par value; 300,000,000 shares authorized as of March 31, 2024 and December 31, 2023; 60,079,778 and 57,910,461 shares issued and outstanding as of March 31, 2024 and December 31, 2023, respectively	6	6
Additional paid-in capital	499,843	489,453
Accumulated deficit	(237,671)	(222,798)
Accumulated other comprehensive income (loss)	(144)	312
Total stockholders’ equity	262,034	266,973
Total liabilities and stockholders’ equity	$ 300,967	$ 310,125